Abstract: A seal portion 24 is arranged between a first fixing surface 222 and a second fixing surface 311. A biasing member 25 comes into contact with a tapered surface 332 of a male terminal 331 received in a female terminal 231 and applies a force in a direction in which the male terminal 331 and the female terminal 231 are moved closer to each other. In a state where the male terminal 331 is received in the female terminal 231, the seal portion 24 is compressed by being sandwiched between the first fixing surface 222 and the second fixing surface 311, and a periphery of the male terminal 331 and the female terminal 231 becomes in a state of being sealed by the seal portion 24.

Abstract: The present invention relates to a compound having inhibitory activity against KRAS G12D mutation or a salt thereof, and relates to a pharmaceutical composition comprising the compound as an active ingredient.

Abstract: A thermoformable nonwoven composite containing a nonwoven layer which contains a plurality of first staple fibers, a plurality of first binder fibers having a first melting point, and a plurality of second binder fibers having a second melting point, wherein the first staple fibers, first binder fibers, and second binder fibers intertwine and cross at crossover points. The difference first melting point and the second melting point differ by at least about 15° C., and at least 95% by weight of all of the fibers in the nonwoven layer are polyester. The thermoformable nonwoven composite also contains a first resin formulation containing a first resin. The first resin is located within the nonwoven and located in at least a portion of the crossover points. The first staple fibers, the first and second binder fibers, and the first resin all contain a polymer from the same chemical class.

Abstract: The present invention provides an antitumor agent comprising a compound or a pharmaceutically acceptable salt thereof that covalently binds to GTP-bound KRASG12C as an active ingredient.

Abstract: A method for manufacturing a liquid discharge head comprising: a substrate, a protective layer covering at least a part of the substrate, and a laminate member formed on the protective layer, wherein the method comprises steps of: forming the protective layer on at least a part of the substrate; forming the laminate member on the protective layer with a part of the protective layer exposed, the protective layer comprises at least Si and C, a content of oxygen in a bulk of the protective layer is less than 20 atomic % in terms of an element composition ratio, a modified layer with a content of oxygen of 20 atomic % or more in terms of an element composition ratio is present on a surface of the protective layer, and a thickness of the modified layer between the protective layer and the laminate member is 3.40 nm or less.

Abstract: A method for producing a liquid-ejection head substrate includes forming a protective film covering the surface of a portion of a cavitation resistant film provided at a position where the heating resistor is covered with a metallic material containing at least one of titanium, tungsten, and titanium tungsten and etching the substrate after forming the protective film.

Abstract: Provided is a method of forming a film on a substrate including: forming a protective member on a surface of the substrate; forming an organic structure on the surface of the substrate, at a distance from the protective member; removing the protective member after the formation of the organic structure; and forming a film by CVD in a region of the surface of the substrate from which the protective member is removed.

Abstract: Provided is a liquid ejection head substrate including: a substrate; a liquid ejection element that generates liquid ejection energy on the substrate; and an electrode pad that is electrically connected to the liquid ejection element, in which the electrode pad includes a barrier metal layer and a bonding layer on the barrier metal layer, and an end side surface of the barrier metal layer is covered with a silicon-based film containing carbon.

Abstract: To provide a biomedical electrode which is capable of restraining displacement or release of the electrode even if a living body takes a hard action, and which is mountable without an occurrence of discomfort. This biomedical electrode has conductive gels 11, 11, retaining members 12, 12 to retain the conductive gels 11, 11, and an adhesive surface 31a, and comprises a sheet-shaped adhesive member 30 to adhere the conductive gels 11, 11 to a living body surface S via the retaining members 12, 12, and further, the adhesive member 30 is formed in an enough size to cover substantially all regions of the retaining members 12, 12, and is configured to have liquid through holes 30b to 30b, 30c, 30c to discharge sweat which is accumulated in internal spaces R, R formed between the living body surface S and the retaining members 12, 12.

Abstract: Provided is a method of forming a film on a substrate including: forming a protective member on a surface of the substrate; forming an organic structure on the surface of the substrate, at a distance from the protective member; removing the protective member after the formation of the organic structure; and forming a film by CVD in a region of the surface of the substrate from which the protective member is removed.

Abstract: Provided is a liquid ejection head substrate including: a substrate; a liquid ejection element that generates liquid ejection energy on the substrate; and an electrode pad that is electrically connected to the liquid ejection element, in which the electrode pad includes a barrier metal layer and a bonding layer on the barrier metal layer, and an end side surface of the barrier metal layer is covered with a silicon-based film containing carbon.

Abstract: To provide a biomedical electrode which is capable of restraining displacement or release of the electrode even if a living body takes a hard action, and which is mountable without an occurrence of discomfort. This biomedical electrode has conductive gels 11, 11, retaining members 12, 12 to retain the conductive gels 11, 11, and an adhesive surface 31a, and comprises a sheet-shaped adhesive member 30 to adhere the conductive gels 11, 11 to a living body surface S via the retaining members 12, 12, and further, the adhesive member 30 is formed in an enough size to cover substantially all regions of the retaining members 12, 12, and is configured to have liquid through holes 30b to 30b, 30c, 30c to discharge sweat which is accumulated in internal spaces R, R formed between the living body surface S and the retaining members 12, 12.

Abstract: A method for treating rheumatoid arthritis, multiple sclerosis, or a disease involving JAK3, including administering a compound of the formula (I) or a salt thereof to a subject

Abstract: Provided is a novel compound having a selective JAK3-inhibitory effect and also having excellent oral absorbability. Also provided is a pharmaceutical agent, which is based on a JAK3-inhibitory effect and is useful for preventing and/or treating a disease involving the JAK3, and in particular, rheumatoid arthritis or multiple sclerosis. An azaindole derivative having a cycloalkenyl group, which is represented by the following formula (I), or a salt thereof, and a pharmaceutical composition containing the same: where R1 to R4, m and n have the same meanings as those defined in the description.

Abstract: A method for treating rheumatoid arthritis, multiple sclerosis, or a disease involving JAK3, including administering a compound of the formula (I) or a salt thereof to a subject

Abstract: Provided is a novel compound having a selective JAK3-inhibitory effect and also having excellent oral absorbability. Also provided is a pharmaceutical agent, which is based on a JAK3-inhibitory effect and is useful for preventing and/or treating a disease involving the JAK3, and in particular, rheumatoid arthritis or multiple sclerosis. An azaindole derivative having a cycloalkenyl group, which is represented by the following formula (I), or a salt thereof, and a pharmaceutical composition containing the same: where R1 to R4, m and n have the same meanings as those defined in the description.

Abstract: A needled, non-woven having a first zone extending from an upper surface to an inner plane and a second zone extending from the inner plane to a lower surface. The first zone comprises a plurality of first core/sheath fibers, a plurality of second fibers, and a plurality of third fibers, The second polymer forming the second fibers and the sheath polymer forming the sheath of the first core/sheath fibers have a critical surface energy less than 40 mN/m. The second zone comprises a plurality of fourth fibers and a plurality of fifth fibers. A portion of the first core/sheath fibers, second fibers, and third fibers from the first zone are physically entangled into the fourth fibers and fifth fibers in the second zone. A consolidated needled non-woven and method for making the needled non-woven and consolidated needled non-woven are also disclosed.

Abstract: A method of manufacturing a liquid ejection head includes forming, on the substrate, a metal layer formed of a first metal, forming a liquid flow path pattern formed of a second metal that is a metal of a different kind from that of the first metal and that is dissolvable in a solution that does not dissolve the first metal, the liquid flow path pattern being formed on at least a part of a surface of the metal layer, covering the metal layer and the pattern with an inorganic material layer to be formed as the nozzle layer, forming the ejection orifices in the inorganic material layer, and removing the pattern by the solution. A standard electrode potential E1 of the first metal and a standard electrode potential E2 of the second metal have a relationship of E1>E2.

Abstract: Provided is a method for manufacturing a substrate for liquid ejection head including an ejection energy generating element and a nozzle layer including an ejection port and a liquid channel. The method includes the steps of: forming, on the substrate including the element, a metal mold member made of metal and having a flat surface, the metal mold member making up at least a part of a mold for the liquid channel, and a planarization layer made of the metal and having a flat surface to planarize a surface of the nozzle layer; coating the mold for the liquid channel and the planarization layer with negative-type photosensitive resin, thus forming a negative-type photosensitive resin layer to be the nozzle layer; exposing the resin layer to ultraviolet rays, thus forming the ejection port; and selectively removing the mold for the liquid channel, thus forming the liquid channel.

Abstract: The present invention provides a compound represented by the following general formula (I) or a salt thereof which has a Syk inhibitory effect (in the formula R1 represents a hydrogen atom or an optionally substituted C1-C6 alkyl group; A represents a hydrogen atom, an optionally substituted C1-C8 alkyl group, an optionally substituted C2-C6 alkenyl group, an optionally substituted C2-C6 alkynyl group, an optionally substituted C3-C10 cycloalkyl group, an optionally substituted C6-C14 aromatic hydrocarbon group, an optionally substituted 4- to 10-membered unsaturated heterocyclic group, or an optionally substituted 4- to 10-membered saturated heterocyclic group, or optionally forms a 4- to 10-membered unsaturated heterocyclic ring or a 4- to 10-membered saturated heterocyclic ring together with R1 and the nitrogen atom bonded thereto; R2 represents a hydrogen atom or an optionally substituted C1-C6 alkyl group; and B represents an optionally substituted unsaturated heterocyclic group).